Immuneering Corp (NASDAQ:IMRX) has a beta value of 0.01 and has seen 1.38 million shares traded in the last trading session. The company, currently valued at $87.80M, closed the last trade at $2.44 per share which meant it lost -$0.12 on the day or -4.69%% during that session. The IMRX stock price is -56.97% off its 52-week high price of $3.83 and 59.02% above the 52-week low of $1.00.
The consensus among analysts is that Immuneering Corp (IMRX) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Immuneering Corp (NASDAQ:IMRX) trade information
Sporting -4.69%% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IMRX stock price touched $2.44 or saw a rise of 21.04%. Year-to-date, Immuneering Corp shares have moved 64.86%, while the 5-day performance has seen it change 28.42%. Over the past 30 days, the shares of Immuneering Corp (NASDAQ:IMRX) have changed 64.86%.
Wall Street analysts have a consensus price target for the stock at $13, which means that the shares’ value could jump 81.23% from current levels. The projected low price target is $3.0 while the price target rests at a high of $41.0. In that case, then, we find that the current price level is -1580.33% off the targeted high while a plunge would see the stock gain -22.95% from current levels.
Immuneering Corp (IMRX) estimates and forecasts
The company’s shares have gained 41.04% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -46.45% over the past 5 years. Earnings growth for 2025 is a modest 15.20% while over the next 5 years, the company’s earnings are expected to increase by 8.75%.
IMRX Dividends
Immuneering Corp is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Immuneering Corp (NASDAQ:IMRX)’s Major holders
The top two institutional holders are CITADEL ADVISORS LLC with over 1.88 million shares worth more than $2.41 million. As of 2024-06-30, CITADEL ADVISORS LLC held 6.4083% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.07 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.37 million and represent 3.6442% of shares outstanding.
